Embleema Company Research Report
Company Overview
Name
Embleema
Mission
Embleema's mission is to advance precision medicine by integrating molecular, clinical, and real-world data to produce unique insights.
Founding Details
- Founder: Robert Chu
- Founded By: No information is available regarding the year of founding.
Key People
- Robert Chu: CEO & Founder, former SVP of Global Technology for IQVIA.
- Nicolas Schmidt: Chief Product Officer, formerly at Withings and Head of Healthcare Products at Nokia.
- Elaine E. Thompson, Ph.D: Vice President, Bioinformatics, with a background in FDA regulations and clinical trials.
- Brittany Sorice: UI/UX Lead, focusing on patient experience.
- Naira Stepanyan: Client Success Manager, experienced in user support and data quality.
Headquarters
16 Pearl Street, Suite 110, Metuchen, NJ 08840
Number of Employees
No information is available.
Revenue
No information is available.
Known For
- Embleema is known for being the only end-to-end data platform for personalized medicine that unifies clinical, real-world, molecular data, analytics, and regulatory submissions.
- Known for their HIVE bioinformatics platform used for expedited regulatory approvals.
Products
HIVE Platform
A comprehensive bioinformatics and regulatory analytics platform for genomic and biomarker data, widely used by the FDA for regulatory decisions.
- Features:
- Versatile Data Retrieval: Open APIs and extensive knowledgebases.
- BioCompute: Ensures full data provenance and standardization.
- Security: Compliant with multiple standards, including HIPAA and GDPR.
- Regulatory Analytics: Facilitates standardized data and FDA-approved algorithms.
- Visualizations & Interpretation: Provides interactive visualizations for data analysis.
Embleema Virtual Software-as-a-Service
A comprehensive platform managing clinical and real-world data from patient recruitment to regulatory submission, offering users full control over data.
Recent Developments
New Products Launched
- HIVE Platform: Now widely available, helps streamline FDA regulatory approval processes.
New Features & Partnerships
- Partnership with CALYM: To offer next-generation clinical trial solutions for lymphoma R&D (December 2022).
- Partnership with CDISC: To develop standards for cell and gene therapy patient monitoring (May 2022).
- Partnership with Epilepsy Foundation and Eisai: To build the EDEN real-world data ecosystem (May 2021).
New Partnerships
- FDA Contract: Awarded a contract to establish a reference database for genomic variants (September 2021).
- Alira Health Partnership: Deploying next-generation real-world data solutions for life sciences (October 2020).
- Gustave Roussy Initiative: Healthcare blockchain initiative to accelerate cancer research (March 2019).
Other Developments
- Techstars Alchemist Accelerator Program: Embleema joined after closing a $3.7M Series A Funding Round (February 2019).
- Launch of First Health Records Blockchain: Empowering patients with control over their health data (July 2018).
Additional Information
Clients & Partners
While specific clients and partners are mentioned in various partnerships, detailed client names are not available.
Contact Information
- Press Inquiries: press@embleema.com
Social Media Presence
- Embleema can be found on platforms like Twitter, Facebook, LinkedIn, and YouTube.
Advisors
- Pascale Witz: Co-Founder & CEO, PWH Advisors
- Pr. Alexander Eggermont: CSO Princess Maxima Center
- Pr. Vahan Simonyan: Chief Scientific Advisor
- Adel Al-Saleh: CEO of T-Systems & Board Member of Deutsche Telekom
- Bernard Gilly, PhD: CEO at GenSight Biologics & Chairman at iBionext
- Pr. Elly Hoseung Lee: Assistant Professor at Gachon University in Korea
